Detalhe da pesquisa
1.
JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib.
Ann Rheum Dis
; 80(7): 865-875, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-33741556
2.
Phase 2 study of idelalisib and entospletinib: pneumonitis limits combination therapy in relapsed refractory CLL and NHL.
Blood
; 127(20): 2411-5, 2016 05 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-26968534
3.
Discovery of highly potent and selective Bruton's tyrosine kinase inhibitors: Pyridazinone analogs with improved metabolic stability.
Bioorg Med Chem Lett
; 26(2): 575-579, 2016 Jan 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-26675441
4.
Potent and selective Bruton's tyrosine kinase inhibitors: discovery of GDC-0834.
Bioorg Med Chem Lett
; 25(6): 1333-7, 2015 Mar 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-25701252
5.
Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis.
Nat Chem Biol
; 7(1): 41-50, 2011 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-21113169
6.
Antiarthritis effect of a novel Bruton's tyrosine kinase (BTK) inhibitor in rat collagen-induced arthritis and mechanism-based pharmacokinetic/pharmacodynamic modeling: relationships between inhibition of BTK phosphorylation and efficacy.
J Pharmacol Exp Ther
; 338(1): 154-63, 2011 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-21521773
7.
Characterization of the mechanism of action of lanraplenib, a novel spleen tyrosine kinase inhibitor, in models of lupus nephritis.
BMC Rheumatol
; 5(1): 15, 2021 Mar 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-33781343
8.
Discovery of Lanraplenib (GS-9876): A Once-Daily Spleen Tyrosine Kinase Inhibitor for Autoimmune Diseases.
ACS Med Chem Lett
; 11(4): 506-513, 2020 Apr 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32292557
9.
An inhibitor of spleen tyrosine kinase suppresses experimental crescentic glomerulonephritis.
Int J Immunopathol Pharmacol
; 32: 2058738418783404, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-29923438
10.
Effects of GS-9876, a novel spleen tyrosine kinase inhibitor, on platelet function and systemic hemostasis.
Thromb Res
; 170: 109-118, 2018 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-30172129
11.
Regulation and function of apoptosis signal-regulating kinase 1 in rheumatoid arthritis.
Biochem Pharmacol
; 151: 282-290, 2018 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29408488
12.
SYK inhibitor entospletinib prevents ocular and skin GVHD in mice.
JCI Insight
; 3(19)2018 10 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-30282825
13.
Pharmacokinetics, Pharmacodynamics, and Safety of Entospletinib, a Novel pSYK Inhibitor, Following Single and Multiple Oral Dosing in Healthy Volunteers.
Clin Drug Investig
; 37(2): 195-205, 2017 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-27785737
14.
Inhibition of Spleen Tyrosine Kinase Reduces Renal Allograft Injury in a Rat Model of Acute Antibody-Mediated Rejection in Sensitized Recipients.
Transplantation
; 101(8): e240-e248, 2017 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-28594748
15.
Targeting B-cell receptor signaling kinases in chronic lymphocytic leukemia: the promise of entospletinib.
Ther Adv Hematol
; 7(3): 157-70, 2016 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-27247756
16.
Discovery of GS-9973, a selective and orally efficacious inhibitor of spleen tyrosine kinase.
J Med Chem
; 57(9): 3856-73, 2014 May 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-24779514
17.
B-cell receptor signaling inhibitors for treatment of autoimmune inflammatory diseases and B-cell malignancies.
Int Rev Immunol
; 32(4): 397-427, 2013 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-23886342